Celldex Therapeutics CLDX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.73M+23.8% | $28.87M-19.9% | $36.04M+56.4% | $23.04M+34.5% | $17.14M-39.6% | ||
| $415.73M-15.1% | $489.7M-10.5% | $547.19M-9.9% | $607.29M-7.4% | $656.16M-5.8% | ||
| $230K-88.6% | $2.02M+2,139% | $90K0.0% | $90K-91.5% | $1.06M+52.0% | ||
| $7.53M-46.5% | $14.08M-33.1% | $21.03M+17.0% | $17.98M-7.3% | $19.4M-8.4% | ||
| $459.22M-14.1% | $534.66M-11.5% | $604.34M-6.8% | $648.4M-6.5% | $693.76M-7.1% | ||
| $7.4M+38.7% | $5.33M+10.5% | $4.83M+9.9% | $4.39M-4.5% | $4.6M+5.9% | ||
| $2.01M-17.4% | $2.44M-10.3% | $2.72M-12.9% | $3.12M-11.2% | $3.51M-9.9% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $15.43M+15.5% | $13.36M+42.7% | $9.36M+0.7% | $9.3M-10.7% | $10.41M+6.8% | ||
| $511.25M-12.3% | $582.98M-10.1% | $648.44M-6.4% | $692.41M-6.4% | $739.47M-6.7% | ||
| $10.36M+778% | $1.18M-72.3% | $4.27M+106% | $2.07M-39.2% | $3.41M+4.4% | ||
| $1.23M0.0% | $1.23M+32.3% | $930K0.0% | $930K-43.7% | $1.65M+75.5% | ||
| $1.47M-5.6% | $1.55M-0.1% | $1.55M+1.1% | $1.54M+2.5% | $1.5M+3.2% | ||
| $51.47M+0.9% | $50.99M+9.7% | $46.47M+41.0% | $32.96M+3.0% | $32.02M-18.9% | ||
| $443K-43.5% | $784K-26.6% | $1.07M-28.6% | $1.5M-22.5% | $1.93M-18.3% | ||
| $3.11M-23.0% | $4.04M+59.0% | $2.54M0.0% | $2.54M0.0% | $2.54M-26.8% | ||
| $55.03M-1.4% | $55.82M+11.5% | $50.08M+35.3% | $37M+1.4% | $36.49M-19.5% | ||
| —— | —— | —— | —— | —— | ||
| $67K0.0% | $67K+1.5% | $66K0.0% | $66K0.0% | $66K0.0% | ||
| $2.35B+0.4% | $2.34B+0.4% | $2.33B+0.4% | $2.32B+0.4% | $2.31B+0.4% | ||
| -$1.89B-4.3% | -$1.81B-4.7% | -$1.73B-4.0% | -$1.67B-3.5% | -$1.61B-3.5% | ||
| $2.52M-30.4% | $3.63M-3.7% | $3.77M+12.8% | $3.34M-6.4% | $3.57M+7.7% | ||
| $456.23M-13.5% | $527.17M-11.9% | $598.36M-8.7% | $655.41M-6.8% | $702.98M-5.9% | ||
| $511.25M-12.3% | $582.98M-10.1% | $648.44M-6.4% | $692.41M-6.4% | $739.47M-6.7% | ||
| $415.73M-15.1% | $489.7M-10.5% | $547.19M-9.9% | $607.29M-7.4% | $656.16M-5.8% | ||
| $15.43M+15.5% | $13.36M+42.7% | $9.36M+0.7% | $9.3M-10.7% | $10.41M+6.8% | ||
| $2.01M-17.4% | $2.44M-10.3% | $2.72M-12.9% | $3.12M-11.2% | $3.51M-9.9% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $2.01M-17.4% | $2.44M-10.3% | $2.72M-12.9% | $3.12M-11.2% | $3.51M-9.9% | ||
| $15.43M+15.5% | $13.36M+42.7% | $9.36M+0.7% | $9.3M-10.7% | $10.41M+6.8% | ||
| $2.01M-17.4% | $2.44M-10.3% | $2.72M-12.9% | $3.12M-11.2% | $3.51M-9.9% | ||
| $15.43M+15.5% | $13.36M+42.7% | $9.36M+0.7% | $9.3M-10.7% | $10.41M+6.8% | ||
| $38.42M-18.3% | $47.03M+18.4% | $39.72M+39.7% | $28.42M+11.7% | $25.46M-24.8% | ||
| $38.42M-18.3% | $47.03M+18.4% | $39.72M+39.7% | $28.42M+11.7% | $25.46M-24.8% | ||
| $1.23M0.0% | $1.23M+32.3% | $930K0.0% | $930K-43.7% | $1.65M+75.5% | ||
| $1.91M-18.3% | $2.34M-10.9% | $2.62M-13.5% | $3.03M-11.6% | $3.43M-10.1% | ||
| $2.35B+0.4% | $2.34B+0.4% | $2.33B+0.4% | $2.32B+0.4% | $2.31B+0.4% | ||
| $67K0.0% | $67K+1.5% | $66K0.0% | $66K0.0% | $66K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Celldex Therapeutics cover its short-term obligations?
- Its current ratio is 8.92 — current assets exceed current liabilities.
- Where does Celldex Therapeutics's balance sheet data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.